BC
QNCX icon

Burleson & Co’s Quince Therapeutics QNCX Stock Holding History

Burleson & Co’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-454
Closed -$283K – 392
2021
Q3 		$283K Buy
+454
New +$7.22M 0.04% 117

Other funds holding QNCX

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Burleson & Co's QNCX Position: Q4 2022 in Review

Burleson & Co reduced its Quince Therapeutics (QNCX) stake by 97% in Q4 2022, selling an estimated $247K and leaving 42 shares worth $5.36K. The position accounts for ﹤0.01% of the portfolio, ranked #302.

Burleson & Co first reported a position in QNCX in Q4 2019 and has held it in 13 quarters since. The position peaked at $12.4M in Q3 2021. 48 funds tracked by Wall St. Rank hold QNCX as of Q4 2022.

  • Burleson & Co held 42 shares of Quince Therapeutics worth $5.36K as of Q4 2022.
  • Burleson & Co sold 1,478 Quince Therapeutics shares in Q4 2022, an estimated $247K.
  • Quince Therapeutics made up ﹤0.01% of Burleson & Co's portfolio in Q4 2022, its #302 holding.
  • Burleson & Co first reported a position in Quince Therapeutics in Q4 2019 and has held it in 13 quarters since.
  • Burleson & Co's Quince Therapeutics position peaked at $12.4M in Q3 2021.
  • 48 funds tracked by Wall St. Rank held Quince Therapeutics as of Q4 2022.

Based on Burleson & Co's 13F filing for Q4 2022, filed 31 Jan 2023.